Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2015-04-28 Earnings Release
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
20150428_PR_AnnualReport_final_EN.pdf
Earnings Release Classification · 95% confidence The document is a press release titled 'Bone Therapeutics Reports 2014 Financial and Operational Results'. It provides a summary of financial highlights, operational updates, and management commentary regarding the 2014 fiscal year. While it contains financial data, it is structured as an initial announcement of results (Earnings Release) rather than the full, audited Annual Report document itself. It follows the standard format of an earnings release, including contact information, forward-looking statements, and a summary P&L table. FY 2014
2015-04-28 English
20150428_PR_AnnualReport_final_FR.pdf
Report Publication Announcement Classification · 95% confidence The document is a press release from Bone Therapeutics announcing the publication of its 2014 annual report. It provides a summary of operational and financial highlights, including clinical trial progress and financial results, but explicitly states it is an announcement of the report's publication ('annonce aujourd'hui la publication de son rapport annuel'). Following the 'Menu vs Meal' rule, since this is a summary announcement of a report rather than the full audited financial report itself, it is classified as a Report Publication Announcement. FY 2014
2015-04-28 French
20150428_PR_AnnualReport_final_NL.pdf
Earnings Release Classification · 95% confidence The document is a press release from Bone Therapeutics titled 'Bone Therapeutics rapporteert financiële en operationele resultaten 2014'. It provides a summary of operational and financial highlights, including revenue, losses, and cash position for the fiscal year 2014. While it contains financial data, it is structured as a press release (Earnings Release) rather than a full statutory Annual Report (10-K). It serves as the initial announcement of the company's annual performance results. FY 2014
2015-04-28 Dutch
BT - BNB 2014.pdf
Annual Report Classification · 95% confidence The document is a formal Belgian 'Comptes Annuels' (Annual Accounts) filing. It contains administrative details, board member lists, and references to the approval of annual accounts by the general assembly. While it is part of the annual reporting process, in the context of the provided categories, it functions as the official annual financial filing for the company. Given the structure and content, it aligns with the '10-K' category, which is the standard classification for comprehensive annual financial reports in this taxonomy. FY 2014
2015-04-28 French
Bone Theraputics-Procuration_AGO_28_05_2015_16h.pdf
AGM Information Classification · 98% confidence The document is titled 'PROCURATION' (Proxy) and contains a form for a shareholder to appoint a representative ('mandataire') to vote at an upcoming 'assemblée générale ordinaire' (Annual General Meeting - AGM) scheduled for May 28, 2015. The agenda items explicitly mention the 'rapport annuel du conseil d'administration' (annual report) and the 'rapport de rémunération' (remuneration report), which are typical topics for an AGM. Since this document is the mechanism for appointing a proxy to attend and vote at the AGM, it is directly related to the Annual General Meeting process. Therefore, the most appropriate classification is AGM Information (AGM-R).
2015-04-28 French
Bone Therapeutics-Information_concerning_the_rights_of_shareholders.pdf
AGM Information Classification · 98% confidence The document explicitly concerns the 'ORDINARY GENERAL MEETING OF THE COMPANY TO BE HELD ON 28 MAY 2015'. It details shareholder rights regarding agenda items, submitting proposals, and asking written questions prior to the meeting. This content is directly related to the procedures and information shared concerning an Annual General Meeting (AGM). While it contains procedural information that might overlap with a Proxy Statement (PSI), the primary focus on the rights leading up to and during the AGM itself, especially concerning agenda setting and voting rights procedures, strongly aligns with the scope of AGM materials. Since it is not the final voting results (DVA) or the formal proxy solicitation document itself, AGM-R is the most appropriate classification for materials detailing shareholder rights and procedures for the AGM.
2015-04-28 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.